Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina Venetia Long et al. · New England Journal of Medicine · 2015
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival. RESULTS: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%). CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Cited by 5,875 works. doi:10.1056/nejmoa1503093 Open-access PDF
Authors
- Caroline Robert
- Jacob Schachter
- Georgina Venetia Long
- Ana Maria Arance
- Jean‐Jacques Grob
- Laurent Mortier
- ADIL I. DAUD
- Matteo Salvatore Carlino
- Catriona M. McNeil
- Michal Lotem
- James Larkin
- Paul C. Lorigan
- Bart Neyns
- Christian U. Blank
- Omid Hamid
- Christine Mateus
- Ronnie Shapira‐Frommer
- Michele Kosh
- Nageatte Ibrahim
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- The blockade of immune checkpoints in cancer immunotherapy
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Enhancement of Antitumor Immunity by CTLA-4 Blockade